Advancing the Development, from Research to Market, of Effective Therapies for RAS-Mutant Cancers Ranging from G12C to Q61 Modalities to Attain Targeted Drugs for Patients in Need
5th Annual RAS-Targeted Drug Development Summit
Personalizing Medicine Via Targeting Oncogenic RAS for Cancer
With the approval of the second-ever KRAS G12C inhibitor, the field can once again celebrate irrevocable proof that RAS is druggable! However, with so many KRAS G12C drugs in clinic, the field is now turning its eyes to the next generation of RAS therapies, specifically those that can target more mutations, more RAS isoforms, and more indications.
And so, the 5th RAS-Targeted Drug Development Summit arrives as the only industry-dedicated, end-to-end forum to accelerate your best-in-class RAS therapies from conception through to commercialization.
Set to unite 150+ key leaders in biopharma and academia in Boston this September, we are eager to tackle emerging resistance mechanisms, assess promising combination approaches and explore novel RAS therapies.
Hear from 45+ expert speakers across 3 jam-packed days of data-driven presentations, interactive workshops, and panel discussions. This is your one-stop shop to hear the hottest clinical updates, better target non-G12C mutations, validate novel targets in the RAS pathway, and experience the next generation of RAS-targeted drugs.
World-Class Speaker Faculty Includes:
Companies on the Program Include:
Hear What Our Past Attendees Have to Say:
“The summit provides an unparalleled platform to discuss the latest breakthroughs in RAS research and clinical development, making it a valuable resource for anyone seeking to stay up-to-date on this critical area of oncology ”
- Lifecyle Leader, KRAS, Roche
"This conference is an exciting and unique opportunity to learn about the latest advancements in RAS research and clinical developments”
- Director, Clinical Biomarkers & Diagnostics, Amgen
The 5th RAS Targeted DD Summit brings experts from both academia and industry together to exchange learnings and further brainstorm on how to tackle this important oncogene - Saskia Brachmann, Associate Director &
Senior Global Project Lead, Novartis
- Saskia Brachmann, Associate Director & Senior Global Project Lead, Novartis
"The 5th RAS Targeted DD Summit is an extraordinary event to strengthen a trusted network of experts in the field of RAS both from academia and industry”
- Chiara Ambrogio, Associate Professor of Molecular Biology, University of Torino